Xeris Biopharma Holdings, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
Business Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607
Mailing Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607
Phone
844-445-5704
Fiscal Year End
1231
EIN
871082097
Financial Overview
FY2025
$383.53M
Total Assets
$111.04M
Cash & Equivalents
$0.00
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 10-K Annual financial report | March 2, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 25, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
Annual Reports
10-K
March 2, 2026
- Achieved robust 28% year-over-year revenue growth in FY 2023, reaching $165 million, with 20-30% growth projected for FY 2024.
- Management targets positive adjusted EBITDA by late 2025, indicating a clear strategic path towards profitability.
Insider Trading
STRONG SELL
6 insiders
9 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.